DK1631251T3 - Tablet til forsinket frigørelse med defineret kernegeometri - Google Patents

Tablet til forsinket frigørelse med defineret kernegeometri

Info

Publication number
DK1631251T3
DK1631251T3 DK04729170.3T DK04729170T DK1631251T3 DK 1631251 T3 DK1631251 T3 DK 1631251T3 DK 04729170 T DK04729170 T DK 04729170T DK 1631251 T3 DK1631251 T3 DK 1631251T3
Authority
DK
Denmark
Prior art keywords
tablet
delayed release
coating
core geometry
defined core
Prior art date
Application number
DK04729170.3T
Other languages
English (en)
Inventor
Guy Vergnault
Christophe Dragan
Pascal Grenier
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33306519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1631251(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of DK1631251T3 publication Critical patent/DK1631251T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04729170.3T 2003-04-24 2004-04-23 Tablet til forsinket frigørelse med defineret kernegeometri DK1631251T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309342 2003-04-24
PCT/IB2004/001693 WO2004093843A1 (en) 2003-04-24 2004-04-23 Delayed release tablet with defined core geometry

Publications (1)

Publication Number Publication Date
DK1631251T3 true DK1631251T3 (da) 2011-10-03

Family

ID=33306519

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04729170.3T DK1631251T3 (da) 2003-04-24 2004-04-23 Tablet til forsinket frigørelse med defineret kernegeometri

Country Status (20)

Country Link
US (6) US8168218B2 (da)
EP (1) EP1631251B1 (da)
JP (1) JP4790597B2 (da)
KR (1) KR101192722B1 (da)
CN (2) CN1777412A (da)
AT (1) ATE512659T1 (da)
AU (1) AU2004231362B2 (da)
BR (1) BRPI0409652A (da)
CA (1) CA2523158C (da)
CY (1) CY1111835T1 (da)
DK (1) DK1631251T3 (da)
ES (1) ES2368066T3 (da)
IL (1) IL171494A (da)
MX (1) MXPA05011446A (da)
PL (1) PL1631251T3 (da)
PT (1) PT1631251E (da)
RU (1) RU2391093C2 (da)
SI (1) SI1631251T1 (da)
WO (1) WO2004093843A1 (da)
ZA (1) ZA200509477B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
DK1615626T3 (da) * 2003-04-24 2010-02-08 Jagotec Ag Tablet med farvet kerne
KR101192722B1 (ko) 2003-04-24 2012-10-18 자고텍 아게 정해진 핵 위치를 가지는 서방성 정제
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
CN101188999B (zh) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 用于递送分散在分散介质中的活性物质的药物传递系统
US20080248107A1 (en) * 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
SI2049123T2 (sl) 2006-08-03 2016-10-28 Horizon Pharma Ag Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida
US8795721B2 (en) * 2006-12-18 2014-08-05 Eatlittle Inc. Device for delivery of a substance
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US10363221B2 (en) * 2007-10-17 2019-07-30 I-Property Holding Corp. Manufacturing solid pharmaceutical dosage forms with visible micro- and nanostructured surfaces and micro- and nanostructured pharmaceutical dosage form
US20090214599A1 (en) * 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations
CA2749646A1 (en) 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
ES2607209T3 (es) 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
EP2651399A2 (en) 2010-12-13 2013-10-23 Purdue Pharma LP Controlled release dosage forms
WO2012085656A2 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
KR20140075807A (ko) 2010-12-23 2014-06-19 퍼듀 퍼머 엘피 탬퍼 저항성 고체 경구 투여 형태
WO2013030726A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Programmed drug delivery
RU2471479C1 (ru) * 2012-02-13 2013-01-10 Общество с ограниченной ответственностью "Агентство редких лекарств и технологий" Фармацевтическая композиция в форме таблетки для перорального введения, содержащая в качестве активного компонента дексаметазон, и способ ее получения
US20130243861A1 (en) * 2012-03-16 2013-09-19 Cadila Healthcare Limited Press-coated tablets of prednisone
JP5818219B2 (ja) * 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
NZ703532A (en) * 2012-07-05 2018-02-23 Taiwan Liposome Co Ltd Methods of treating arthritis
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
WO2016114726A1 (en) * 2015-01-12 2016-07-21 Ilko Ilaç Sanayi Ve Ticaret Anonim Şirketi Time-controlled prednisone delayed release tablet
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CA3047325A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
CN114588124B (zh) * 2020-12-07 2023-10-20 江苏恒瑞医药股份有限公司 一种延迟释放的药物组合物
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874586A (en) 1957-10-28 1961-08-10 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
DK0537139T3 (da) 1990-07-02 1994-08-22 Boehringer Mannheim Gmbh Fremgangsmåde til fremstilling af formede, pressede dosisenheder med forsinket frigørelse og dertil svarende dosisenhed
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
WO1992011845A1 (en) 1991-01-03 1992-07-23 Glaxo Canada Inc. Method for production of solid pharmaceutical preparation
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
AU3949093A (en) 1992-03-31 1993-11-08 Benzon Pharma A/S A pharmaceutical formulation
EP0662824A1 (en) 1992-09-30 1995-07-19 Pfizer Inc. Article containing a core and a coating having a non constant thickness
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5567969A (en) * 1995-04-20 1996-10-22 Hall; John H. Compound modulated integrated transistor structure with reduced bipolar switch back effect
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
AU739261B2 (en) 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
IL135502A (en) 1997-10-09 2006-07-05 Dexcel Pharma Technologies Ltd A system that completely suspends the release of a drug in the gastrointestinal tract
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
CA2327685C (en) 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
GB9905898D0 (en) * 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
EP1074249A1 (en) 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
JP5005157B2 (ja) 2001-03-13 2012-08-22 ペンウェスト ファーマシューティカルズ カンパニー 時間治療（ｃｈｒｏｎｏｔｈｅｒａｐｅｕｔｉｃ）投与形態
BR0212950A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas tendo uma porção inserida
JPWO2003075919A1 (ja) 2002-03-14 2005-06-30 第一サントリーファーマ株式会社 塩酸ピルジカイニド含有錠剤（乾式）
RU2005108609A (ru) 2002-09-28 2006-03-10 МакНЕЙЛ-ППС, ИНК. (US) Лекарственные формы с модифицированным высвобождением, имеющие два ядра и отверстие
DK1615626T3 (da) 2003-04-24 2010-02-08 Jagotec Ag Tablet med farvet kerne
KR101192722B1 (ko) 2003-04-24 2012-10-18 자고텍 아게 정해진 핵 위치를 가지는 서방성 정제
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
MXPA06003101A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
DE102004043863A1 (de) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum

Also Published As

Publication number Publication date
US20160256396A1 (en) 2016-09-08
WO2004093843A1 (en) 2004-11-04
SI1631251T1 (sl) 2011-10-28
US9884021B2 (en) 2018-02-06
MXPA05011446A (es) 2006-05-31
EP1631251A1 (en) 2006-03-08
US9040085B2 (en) 2015-05-26
US8168218B2 (en) 2012-05-01
CN102525993A (zh) 2012-07-04
CA2523158A1 (en) 2004-11-04
PT1631251E (pt) 2011-09-19
BRPI0409652A (pt) 2006-04-25
KR20060015528A (ko) 2006-02-17
US8309124B2 (en) 2012-11-13
US20120177739A1 (en) 2012-07-12
CY1111835T1 (el) 2015-10-07
US20120177734A1 (en) 2012-07-12
CN1777412A (zh) 2006-05-24
US20070110807A1 (en) 2007-05-17
CN102525993B (zh) 2017-04-12
US9186332B2 (en) 2015-11-17
RU2391093C2 (ru) 2010-06-10
US8394407B2 (en) 2013-03-12
AU2004231362B2 (en) 2009-11-12
AU2004231362A1 (en) 2004-11-04
RU2005132451A (ru) 2006-06-10
ATE512659T1 (de) 2011-07-15
ZA200509477B (en) 2006-09-27
JP4790597B2 (ja) 2011-10-12
JP2006524229A (ja) 2006-10-26
ES2368066T3 (es) 2011-11-14
KR101192722B1 (ko) 2012-10-18
US20130122061A1 (en) 2013-05-16
EP1631251B1 (en) 2011-06-15
PL1631251T3 (pl) 2011-12-30
CA2523158C (en) 2010-11-16
US20140328912A1 (en) 2014-11-06
IL171494A (en) 2011-04-28

Similar Documents

Publication Publication Date Title
DK1631251T3 (da) Tablet til forsinket frigørelse med defineret kernegeometri
NO20053245L (no) Tabletter med modifisert frigjoring av bupropionhydroklorid.
ATE536862T1 (de) Retardtabletten mit hydromorphon
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
UA88509C2 (ru) Сублингвальная таблетка с покрытием, которое содержит опиоидный анальгетик
DK0779807T3 (da) Fremgangsmåde til fremstilling af en kappetablet med spids kerne
SG164375A1 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
NO20032363D0 (no) Doseringsanordning for modifisert frigivelse
ATE268593T1 (de) Bupropionhydrochlorid enthaltende tabletten mit gesteuerter wirkstoffabgabe
CA2363902A1 (en) Process and system for controlled-release drug delivery
ITFI20050206A1 (it) Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
WO2005027843A3 (en) Chronotherapeutic dosage forms
NO20080175L (no) Sukkerbelagt tablett
TW200517146A (en) Novel composition
WO2005079763A3 (en) Compression-coated tablets and manufacture thereof
DE60002089D1 (de) Niedrig dosierte tabletten, und verfahren zur herstellung
MY139719A (en) Oral dosage form for controlled drug release
ATE328587T1 (de) Feste pharmazeutische zusammensetzung enthaltend tilidinhydrochlorid
WO2011093612A3 (en) Oral complex composition comprising pseudoephedrine and levocetirizine
MX2021014339A (es) Preparacion de granulo inhibidor de parp y proceso de preparacion del mismo.
MXPA05003279A (es) Forma de dosis de liberacion modificada.
ES2199681A1 (es) Una forma farmaceutica solida para piensos substancialmente granular y no pulverulenta.
GT200500342A (es) Tableta de liberacion modificada del clorhidrato de bupropion